Methylphenidate for ADHD and Cannabis Use Disorder

This trial tests the effectiveness of delayed-release, extended-release methylphenidate, already approved for ADHD, in individuals with both ADHD and Cannabis Use Disorder. Researchers aim to determine if this medication reduces ADHD symptoms more effectively than a placebo (a pill with no active medicine). Participants will take the medication or placebo nightly for 12 weeks and report on their symptoms and cannabis use. This trial may suit individuals aged 16-26 who have both ADHD and Cannabis Use Disorder, frequently use cannabis, and are interested in or currently receiving help for their cannabis use. As a Phase 4 trial, this research explores how an FDA-approved treatment can benefit more patients.

Research has shown that delayed-release, extended-release methylphenidate is generally well-tolerated. Studies have found that this medication significantly improves daily functioning in people with ADHD compared to a placebo. In these studies, patients did not report any serious side effects. The FDA has already approved this type of methylphenidate for treating ADHD, indicating its well-established safety.

Most treatments for ADHD and Cannabis Use Disorder typically involve standard stimulant medications or behavioral therapies. However, delayed-release, extended-release methylphenidate is unique because it offers a novel delivery method designed to provide a steady release of medication throughout the day. This could potentially enhance symptom management with fewer doses, which is convenient for patients who struggle with adherence. Researchers are excited about this treatment because it could improve focus and reduce impulsivity with potentially lower side effects, making it a promising option for those dealing with both ADHD and Cannabis Use Disorder.

Research has shown that a special form of methylphenidate, which releases slowly in the body, effectively treats ADHD. Studies have found that it greatly improves attention and reduces impulsive behavior in both teenagers and adults with ADHD. This trial will compare the effects of delayed-release, extended-release methylphenidate with a placebo. The medication helps people focus better and make decisions more easily. For those with both ADHD and substance use issues, such as cannabis problems, evidence suggests that stimulants like methylphenidate can be used safely and effectively. The FDA has already approved this treatment for ADHD, supporting its use in managing symptoms of this condition.⁶⁷⁸⁹¹⁰